logo

For the Inventor, By the Inventor

Cambridge, United Kingdom

Nxera Pharma UK Limited

Calculating rank
USPTO Granted Patents = 18


Trademarks = 1

Forward Citations = 0

Loading Chart...
Loading Chart...

34 inventors (with patents filed for the assignee):

goldMedal Miles Stuart Congreve (15 out of 97 patents)

silverMedal Giles Albert Brown (14 out of 69 patents)

bronzeMedal Nigel Alan Swain (9 out of 10 patents)

4.  Benjamin Gerald Tehan (6 out of 60 patents)

5.  John Andrew Christopher (5 out of 24 patents)

6.  Sarah Joanne Bucknell (5 out of 13 patents)

7.  Francesca Deflorian (5 out of 13 patents)

8.  Mark Pickworth (5 out of 40 patents)

9.  Jonathan Stephen Mason (4 out of 16 patents)

10.  Stephen Paul Watson (4 out of 4 patents)

11.  Michael Alistair O'brien (4 out of 4 patents)

12.  Julie Elaine Cansfield (3 out of 29 patents)

13.  Stephen Philippe Andrews (3 out of 7 patents)

14.  Barry John Teobald (2 out of 22 patents)

15.  Charlotte Fieldhouse (2 out of 14 patents)


18 patents:

1. 12774289 - H4 antagonist compounds (2026-10-27),
2. 12729189 - GPR52 modulator compounds (2026-09-08),
3. 12655120 - GPR52 modulator compounds (2026-06-16),
4. 12552799 - Triazolone compounds (2026-02-17),
5. 12528815 - 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer (2026-01-20),
6. 12492174 - Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases (2025-12-09),
7. 12441777 - GLP-1 receptor antagonists (2025-10-14),
8. 12415795 - 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators (2025-09-16),
9. 12344621 - CGRP antagonist compounds (2025-07-01),
10. 12331029 - Orexin 1 receptor antagonists (2025-06-17),
11. 12291512 - Oxime compounds as agonists of the muscarinic Mand/or Mreceptor (2025-05-06),
12. 12240825 - Oxexin 1 receptor antagonists (2025-03-04),
13. 12234227 - Pyrazole derivatives as H4 antagonist compounds (2025-02-25),
14. 12227521 - CGRP antagonist compounds (2025-02-18),
15. 12215099 - Quinolinone and benzoxazine derivatives as muscarinic Mand/or Mreceptor agonists (2025-02-04),
Company Overview
Nxera Pharma UK Limited is a biotechnology company based in Cambridge, specializing in the development of innovative therapeutic solutions. The organization focuses on advancing drug discovery and formulation technologies, particularly in the fields of oncology and rare diseases. With a commitment to addressing unmet medical needs, Nxera Pharma leverages cutting-edge research and collaborative partnerships to enhance treatment options and improve patient outcomes in the global healthcare landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

18 Patents

#61 in Cambridge

#1,001 in United Kingdom

#34,263 in the World

Cambridge, GB
Cambridge, United Kingdom

Nxera Pharma UK Limited

Forward Citations = 0

34 inventors:

goldMedal Miles Stuart Congreve (15 out of 97 patents)

silverMedal Giles Albert Brown (14 out of 69 patents)

bronzeMedal Nigel Alan Swain (9 out of 10 patents)

4.  Benjamin Gerald Tehan (6 out of 60 patents)

5.  John Andrew Christopher (5 out of 24 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Nxera Pharma UK Limited. Retrieved from https://idiyas.com/company/nxera-pharma-uk

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…